CD19 CAR T cell product and disease attributes predict leukemia remission durabilityOlivia Finney, Michael C. Jensen, Hannah Brakke et al.|Journal of Clinical Investigation|2019Cited by 355
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysisNicholas A. Vitanza, Julie R. Park, Adam Johnson et al.|Nature Medicine|2021Cited by 319
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and SafetyNicholas A. Vitanza, Julie R. Park, Lei Zhao et al.|Cancer Discovery|2022Cited by 277
Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapyJuliane Gust, Rebecca Gardner, Olivia Finney et al.|Annals of Neurology|2019Cited by 191
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trialNicholas A. Vitanza, Michael C. Jensen, Rebecca Ronsley et al.|Nature Medicine|2025Cited by 154